The companies will work together to identify novel biomarkers of the rare genetic disorder Angelman syndrome.
Baylor College of Medicine, Illumina, Aushon Biosystems, SciGene, Invitrogen
Baylor will use the arrays for studying genomic imprinting and its role in developmental diseases.
Quest plans to develop and sell a diagnostic for prostate cancer based on the biomarker.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.